Our company has worked on a lot of projects involving excipients and pharmaceutical active ingredients. We are proud to have worked with some of the biggest, most reputed API manufacturers of the world.
We provide services to develop and validate testing methods, including stress testing and photostability when required, as well as ICH stability studies. Pharmaceutical ingredient manufacturers are facing a lot of analytical challenges due to the new requirements regarding residual solvents, genotoxic impurities and elemental impurities. Furthermore, microbiological testing is also required nowadays, for both sterile and non-sterile ingredients.
Chemistry, manufacturing and control analytical services are conducted under GMP compliance. During development, some phases may be executed according to GLP at the Client's request.
REQUEST A QUOTATION |
We provide particle size distribution analysis, including method development and validation in solid products or suspension under GMP compliance. Using an instrument Mastersizer 3000 laser diffraction particle size analyzer which delivers rapid, accurate particle size distributions for both wet and dry dispersions.
Nitrosamine compounds are potent genotoxic carcinogens in several non-human species and are classified as probable human carcinogens by the International Agency for Research on Cancer (IARC).
Since June 2018, several N-nitrosamines have been detected in several batches of drug substances, initially from Sartans, but now the concern of the heath agencies has been extended to all drug substances and also to drug products.
Working with biologic drugs involves a huge analytical effort to understand the characteristics of the whole molecule in depth. Various methods and technologies are requires to get the analytical fingerprint of the molecule. An extensive analytical characterization based on an orthogonal approach is a key element for the project's success. We offer complex characterization projects for innovative biologics and comparison of biosimilars.
We have extensive experience performing analytical tests for APIs, excipients, intermediate products, finished products, packaging materials and process environment samples. The most suitable method is used, according to customer specifications or the relevant Pharmacopoeias description (EP, USP, BP, JP). If non-compendial methods need to be used, we develop and validate the method from scratch or transfer the method from the manufacturer.
We have a comprehensive knowledge in the development and validation of analytical proprietary and non-proprietary methods for excipients, APIs, intermediate products and finished products, according to the ICH Q2 (R1) in line with Q6A and Q6B. Our methods are ready for transfer to contract-giver, in compliance with EU-GMP chapter 6, performing a comparative test, a co-validation in two sites or a revalidation.
We provide full CH studies and on-going stability programmes for third parties. These services, at the client's request, can include: method transfer, method improvement, analytical standards management, storage at different conditions, scheduling of analytical timepoints, full analysis and out-of-trend (OOT) and out-of-specification (OOS) management. These tasks are always conducted according to procedures agreed upon with the client.
We provide microbiological testing for sterile and non-sterile APIs and drug products. Our fully-equipped laboratory includes a cleanroom with airlock technology and HEPA filters for the most sensitive operations. Our 4-glove isolator ISOFLEX-S is equipped with a Steritest pump and an H2O2 generator. The main advantage of using isolation technology for sterility testing is to ensure that no fals- positive results are obtained.
We provide Elemental Impurities testing using ICP-MS according to ICH Q3D and European Pharmacopoeia and USP General Chapters <232>, <233> and <2232> for drug substances, excipients and drug products, including the 24 elements listed in the ICH Q3D guideline and/or others.
Revised monographs in the European Pharmacopoeia on heparin sodium (0333) and heparin calcium (0332) are in force from January 1st, 2015. These monographs include chromogenic anti-factor IIa and anti-factor Xa assays. The USP monograph for heparin sodium had been updated previously.
We have implemented and validated these challenging assays according to the USP monograph and they are ready to be used for drug products and drug substances. However, personalized method adjustments are necessary on a case-by-case basis.
Cleaning validation is a significant GMP activity to prevent contamination of biopharmaceutical products by ensuring that the processing equipment is suitable for later manufacturing processes. Potential contaminants include residues of the active pharmaceutical ingredients or their related substances, and residues from the products used during the cleaning process such as solvents or detergents. This is particularly important for highly-sensitizing compounds such as antibiotics, hormones and cytotoxics and in the case of parenteral drug products.
Chemistry, manufacturing and control analytical services are conducted under GMP compliance. During development, some phases may be executed according to GLP at the Client's request.
REQUEST A QUOTATION |
We offer you our experience in studies on Percutaneous Absorption for topical semisolid drug products using vertical diffusion cells (or Franz cells) according to the EMA Draft Guideline on Quality and equivalence of topical products. Both In Vitro Release Test and In Vitro Permeation Test are available using the Hanson difussion Phoenix instrument.
